73 results
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Third party tender offer statement (amended)
6:59am
diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
4 Dec 23
Third party tender offer statement (amended)
7:04am
care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
17 Nov 23
Third party tender offer statement (amended)
6:53am
care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions
SC TO-T/A
EX-99
PNT
POINT Biopharma Global Inc.
15 Nov 23
Third party tender offer statement (amended)
6:51am
diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing
SC TO-T/A
EX-99
yrtgmdd9 wk3mh8m2j8
8 Nov 23
Third party tender offer statement (amended)
5:06pm
SC TO-T
EX-99
4ld7te397
13 Oct 23
Third party tender offer statement
6:52am
SC14D9C
EX-99.2
n55z8 47t8bdk
3 Oct 23
Written communication relating to third party tender offer
5:24pm
SC TO-C
EX-99.1
jfoewy99hnz4clanfcs9
3 Oct 23
Information about tender offer
4:30pm
SC14D9C
EX-99.4
pv8pxp1otptzin9e26
3 Oct 23
Written communication relating to third party tender offer
7:37am
8-K
EX-99.4
o2adgzy9cdy8hdlc 66d
3 Oct 23
Tender and Support Agreement
7:35am
ARS
nkz1suzl
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
g2yzqkkiusqvy4a
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
8-K
EX-99.2
08200n2lxii
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am